Cullinan Management Inc (CGEM)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Owen Hughes
Employees:
20
ONE MAIN STREET, CAMBRIDGE, MA 02142
617-410-4655

We are a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Data derived from most recent annual or quarterly report
Market Cap 597.309 Million Shares Outstanding44.609 Million Avg 30-day Volume 511.769 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.36
Price to Revenue0.0 Debt to Equity0.0 EBITDA-185.014 Million
Price to Book Value1.1198 Operating Margin0.0 Enterprise Value60.609 Million
Current Ratio18.677 EPS Growth0.232 Quick Ratio18.245
1 Yr BETA 1.7869 52-week High/Low 30.33 / 7.3 Profit Margin0.0
Operating Cash Flow Growth-142.9431 Altman Z-Score14.4999 Free Cash Flow to Firm -85.112 Million
Earnings Report2022-08-09
View SEC Filings from CGEM instead.

View recent insider trading info

Funds Holding CGEM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CGEM BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-24:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-12-16:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    1.9 Million total shares from 9 transactions

    Open Market Sells (S)

    520.6 Thousand total shares from 7 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GADICKE ANSBERT

    • Director
    16,475 2022-06-22 10

    EBELING THOMAS

    • Director
    16,475 2022-06-22 2

    WEBSTER STEPHEN W

    • Director
    16,475 2022-06-22 2

    ROSENBERG ANTHONY

    • Director
    16,475 2022-06-22 2

    F2 BIOSCIENCE I 2017 LTD

    JOVAN-EMBIRICOS MORANA

    • 10% Owner
    4,430,964 2022-06-21 4

    AHMED NADIM PRESIDENT AND CEO

    • Officer
    • Director
    8,090 2022-06-06 4

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    7,415,823 2022-06-01 4

    F2 VISION SCS

    JOVAN-EMBIRICOS MORANA

    • 10% Owner
    4,532,867 2022-05-12 4

    MARTIN ANNE-MARIE

    • Director
    0 2022-03-01 2

    JONES JEFFREY ALAN CHIEF MEDICAL OFFICER

    • Officer
    0 2022-02-28 2

    BAEUERLE PATRICK SEE REMARKS

    • Officer
    453,934 2022-02-11 3

    KEANE RAYMOND T CHIEF LEGAL OFFICER

    • Officer
    69,124 2022-02-11 1

    ZAWEL LEIGH SEE REMARKS

    • Officer
    134,785 2022-02-11 9

    SAVILL CORRINE ACTING CHIEF BUSINESS OFFICER

    • Officer
    242,615 2022-02-11 1

    MICHAELSON JENNIFER CHIEF DEVELOPMENT OFFICER

    • Officer
    108,411 2022-02-11 5

    TRIGILIO JEFFREY CHIEF FINANCIAL OFFICER

    • Officer
    114,750 2022-02-11 3

    JOVAN-EMBIRICOS MORANA

    • Director
    7,800 2021-09-16 4

    UBS ONCOLOGY IMPACT FUND L.P.

    ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

    BIOIMPACT CAPITAL LLC

    • 10% Owner
    7,648,268 2021-09-16 8

    UBS ONCOLOGY IMPACT FUND L.P.

    ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

    MPM ONCOLOGY IMPACT MANAGEMENT GP LLC

    MPM ONCOLOGY IMPACT MANAGEMENT LP

    • 10% Owner
    7,805,483 2021-08-23 8

    JOVAN-EMBIRICOS MORANA

    GLOBEWAYS HOLDINGS LTD

    F2 VISION SCS

    F2 BIOSCIENCE I 2017 LTD

    F2 MG LTD

    F2 - TPO INVESTMENTS LLC

    F2 BIO TD, LLC

    F2 MC, LLC

    F2 GC, LLC

    • Director
    • 10% Owner
    6,139,339 2021-01-12 4

    HUGHES OWEN PRESIDENT AND CEO

    • Officer
    • Director
    506,226 2021-01-12 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    F2 BIOSCIENCE I 2017 LTD - > 10% Owner

    JOVAN-EMBIRICOS MORANA - > 10% Owner

    2022-06-23 18:47:26 -0400 2022-06-23 S 29,631 $13.00 d 537,392 direct

    F2 BIOSCIENCE I 2017 LTD - > 10% Owner

    JOVAN-EMBIRICOS MORANA - > 10% Owner

    2022-06-23 18:47:26 -0400 2022-06-22 S 49,953 $12.70 d 567,023 direct

    EBELING THOMAS - Director

    2022-06-23 18:23:56 -0400 2022-06-22 A 16,475 a 16,475 direct

    GADICKE ANSBERT - Director

    2022-06-23 18:22:01 -0400 2022-06-22 A 16,475 a 16,475 direct

    WEBSTER STEPHEN W - Director

    2022-06-23 18:18:11 -0400 2022-06-22 A 16,475 a 16,475 direct

    ROSENBERG ANTHONY - Director

    2022-06-23 18:16:04 -0400 2022-06-22 A 16,475 a 16,475 direct

    F2 BIOSCIENCE I 2017 LTD - > 10% Owner

    JOVAN-EMBIRICOS MORANA - > 10% Owner

    2022-06-23 18:47:26 -0400 2022-06-21 S 22,319 $12.77 d 616,976 direct

    AHMED NADIM - Director - Officer PRESIDENT AND CEO

    2022-06-07 16:33:16 -0400 2022-06-06 P 8,090 $12.40 a 8,090 direct -4.2066 -12.1033 0.0 1 -12.1033 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-06-03 18:24:30 -0400 2022-06-01 P 301,009 $11.00 a 2,992,808 direct 7.0033 -1.9544 10.342 3 -1.9544 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-06-03 18:24:30 -0400 2022-06-01 P 44,746 $11.00 a 364,161 direct 7.0033 -1.9544 10.342 3 -1.9544 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-06-03 18:24:30 -0400 2022-06-01 P 405,641 $11.00 a 4,058,854 direct 7.0033 -1.9544 10.342 3 -1.9544 6

    F2 VISION SCS - > 10% Owner

    JOVAN-EMBIRICOS MORANA - > 10% Owner

    2022-05-16 20:54:53 -0400 2022-05-16 S 35,158 $11.23 d 1,305,873 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    F2 VISION SCS - > 10% Owner

    JOVAN-EMBIRICOS MORANA - > 10% Owner

    2022-05-16 20:54:53 -0400 2022-05-13 S 34,189 $10.48 d 1,341,031 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    F2 VISION SCS - > 10% Owner

    JOVAN-EMBIRICOS MORANA - > 10% Owner

    2022-05-16 20:54:53 -0400 2022-05-13 S 85,319 $9.96 d 1,375,220 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-05-16 19:34:33 -0400 2022-05-13 P 17,744 $9.14 a 319,415 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-05-16 19:34:33 -0400 2022-05-13 P 38,558 $9.14 a 2,691,799 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-05-16 19:34:33 -0400 2022-05-13 P 53,598 $9.14 a 3,653,213 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-05-16 19:34:33 -0400 2022-05-12 P 542,999 $9.06 a 3,599,615 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    F2 VISION SCS - > 10% Owner

    JOVAN-EMBIRICOS MORANA - > 10% Owner

    2022-05-16 20:54:53 -0400 2022-05-12 S 264,072 $9.25 d 1,460,539 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    BVF PARTNERS L P/IL - > 10% Owner

    BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

    BVF I GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

    BVF II GP LLC SEE EXPLANATION OF RESPONSES

    BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

    BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

    BVF GP HOLDINGS LLC - > 10% Owner

    BVF INC/IL - > 10% Owner

    LAMPERT MARK N - > 10% Owner

    2022-05-16 19:34:33 -0400 2022-05-12 P 457,001 $9.06 a 2,653,241 direct -5.6432 -12.1162 0.0 1 -12.1162 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 22:15:03 UTC 0.5497 1.0203 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 21:45:03 UTC 0.5497 1.0203 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 21:15:04 UTC 0.5497 1.0203 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 20:45:03 UTC 0.5279 1.0421 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 20:15:03 UTC 0.5279 1.0421 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 19:45:03 UTC 0.5279 1.0421 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 19:15:03 UTC 0.5279 1.0421 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 18:45:03 UTC 0.3051 1.2649 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 18:15:04 UTC 0.3051 1.2649 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 17:45:03 UTC 0.3051 1.2649 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 17:15:03 UTC 0.3051 1.2649 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 16:45:03 UTC 0.2876 1.2824 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 16:15:03 UTC 0.2876 1.2824 550000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 15:45:03 UTC 0.2876 1.2824 7000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 15:15:03 UTC 0.2876 1.2824 10000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 14:45:03 UTC 0.5434 1.0266 10000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 14:15:03 UTC 0.5434 1.0266 10000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 13:45:03 UTC 0.5434 1.0266 10000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 13:15:03 UTC 0.5434 1.0266 10000
    CULLINAN ONCOLOGY INC CGEM 2022-06-24 12:45:03 UTC 0.5434 1.0266 10000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund CGEM -1200.0 shares, $-12564.0 2022-03-31 N-PORT

    Elevate your investments